Medical Properties Trust Insider Award: 25,058 TSR Shares, 59,743 Time-Vested
Rhea-AI Filing Summary
Insider purchases and performance awards at Medical Properties Trust (MPW) The report shows that Kevin James Hanna, Senior VP, Controller & CAO, was granted and acquired a total of 84,801 shares of MPW common stock on 09/24/2025 through two separate awards: 59,743 time-vested shares that vest quarterly through March 31, 2028, and 25,058 performance-based shares tied to three-year total shareholder return (TSR) hurdles ending April 14, 2028. Following these transactions, the reporting person beneficially owns 449,231 shares in total. The performance award vests only if TSR targets (20%, 40%, 60%) are met, with potential upside up to 300% of the target award and post-performance quarterly vesting or earlier full vesting upon final committee determination.
Positive
- Insider acquisition: Reporting person acquired a total of 84,801 shares, increasing beneficial ownership to 449,231 shares.
- Performance alignment: 25,058 shares are tied to TSR hurdles, linking compensation to long-term shareholder returns.
- Staged vesting: 59,743 shares vest quarterly through March 31, 2028, which supports retention and gradual alignment with shareholders.
Negative
- None.
Insights
TL;DR: Senior finance officer received both time-based and performance-based equity awards, increasing beneficial ownership materially.
The Form 4 discloses issuance of 59,743 time-vested shares and 25,058 performance-contingent shares to the companys Senior VP, Controller & CAO, increasing reported beneficial ownership to 449,231 shares. The time-based tranche vests quarterly through March 2028, providing staged alignment with shareholder outcomes. The performance tranche depends on three-year TSR hurdles with incremental payoffs (100% at 20% TSR up to 300% at 60% TSR) and uses a 20-trading-day trailing average to determine payout. For investors, this is an internal compensation disclosure showing management equity stake and potential dilution tied to performance metrics.
TL;DR: Award structure mixes time-based vesting and aggressive TSR-linked performance multipliers, aligning pay with long-term stock performance.
The combination of quarterly time vesting and a multi-tiered TSR performance award indicates a mix of retention and incentive objectives. The performance awards linear interpolation and final committee determination clauses mean actual earned shares will be calculated post-period and could vest in full upon committee determination, subject to continued employment. The disclosed mechanics are detailed and enforceable; they define both upside for strong TSR and delayed realization risk for the grantee.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common stock, par value $0.001 | 59,743 | $0.00 | -- |
| Grant/Award | Common stock, par value $0.001 | 25,058 | $0.00 | -- |
Footnotes (1)
- Shares vest at the beginning of each calendar quarter ending March 31, 2028. The shares were granted under the Medical Properties Trust, Inc. ("the Company") Amended and Restated 2019 Equity Incentive Plan and will be earned based on the achievement of specified Company total shareholder return ("TSR") hurdles during the three-year period ending April 14, 2028 as follows: (i) if the Company's TSR reaches 20%, 100% of the shares will be earned; (ii) if the Company's TSR reaches 40%, 200% of the shares will be earned; and (iii) if the Company's TSR reaches 60%, 300% of the shares will be earned. The actual number of shares to be earned will be determined based on the trailing 20-trading day average, determined quarterly; provided, however, following the end of such three-year performance period, achievement of performance between specific TSR hurdles described above will be determined using straight line linear interpolation (continued on footnote 3). Earned shares will become vested in equal quarterly installments over one year following the date the shares are earned, provided that all unvested earned shares will vest in full on the date that the Compensation Committee makes the final determination regarding performance metrics following the end of the three-year performance period, subject to the grantee's continued employment through such date.
